The new pregnancy and lactation labeling rule

P and T

Volumn 41, Issue 11, 2016, Pages 713-715

  Pernia, Sonia ^a   Demaagd, George ^b  

^a General Hospital   (United States)

^b UNION UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; DOXYLAMINE; FLUCONAZOLE; FOLIC ACID; LEVOTHYROXINE; LISINOPRIL; LITHIUM; LORATADINE; METHOTREXATE; METOPROLOL; ONDANSETRON; PHENYTOIN; SERTRALINE; SIMVASTATIN; WARFARIN;

ARTICLE; CONTRACEPTION; DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; INFERTILITY; LACTATION; PATIENT ATTITUDE; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 84994323518     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy 2014;34(4):389–395.
2. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Fed Regist 2014;79(233): 72064–72103. Available at: www.gpo.gov/fdsys/pkg/FR-2014-12- 04/pdf/2014-28241.pdf. Accessed February 13, 2016.
3. Food and Drug Administration. Pregnancy, lactation, and reproductive potential: labeling for human prescription drug and biological products—content and format: guidance for industry. December 2014. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM425398.pdf. Accessed February 27, 2016.
4. Moseley JF 2nd, Smith LL, Dezan MD. An overview of upcoming changes in pregnancy and lactation labeling information. Pharm Pract (Granada) 2015;13(2):605.
5. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling—proposed rule. Fed Regist 2008:73(104):30831–30868. Available at: www.regulations.gov/ contentStreamer?documentId=FDA-2006-N-0515-0001&disposit ion=attachment&contentType=pdf. Accessed February 13, 2016.
6. Decision Partners, LLC. Evaluation of how best to communicate to healthcare providers about the risks and benefits of prescription drug use for pregnant and nursing women: a mental models research report. September 2009. Available at: www.fda.gov/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/default.htm. Accessed March 19, 2016.
7. Food and Drug Administration. Agency information collection activities; submission for Office of Management and Budget review; comment request; mental models study of communicating with health care providers about the risks and benefits of prescription drug use for pregnant and nursing women with chronic conditions. August 25, 2008. Available at: www.fda.gov/ohrms/dockets/98fr/E8-19653.htm. Accessed March 19, 2016.
8. Greene MF. FDA drug labeling for pregnancy and lactation drug safety monitoring systems. Semin Perinatol 2015;39(7):520–523.
9. Gruber MF. The U.S. FDA pregnancy lactation and labeling rule–Implications for maternal immunization. Vaccine 2015;33(47):6499–6500.
10. Food and Drug Administration. Novel drugs 2015. January 2016. Available at: www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DrugInnovation/UCM485053.pdf. Accessed February 13, 2016.
11. Food and Drug Administration. Novel drug approvals for 2016. September 21, 2016. Available at: www.fda.gov/Drugs/DevelopmentApproval- Process/DrugInnovation/ucm483775.htm. Accessed March 23, 2016.
12. Tresiba (insulin degludec injection) prescribing information. Bagsvaerd, Denmark: Novo Nordisk; 2015. Available at: www.tresibapro.com/about-Tresiba.html. Accessed April 5, 2016.
13. Briviact (brivaracetam) prescribing information. Smyrna, Georgia: UCB, Inc.; 2016. Available at: www.briviact.com/briviact-PI.pdf. Accessed April 5, 2016.
14. Anthim (obiltoxaximab) prescribing information. Pine Brook, New Jersey: Elusys Therapeutics, Inc.; 2016. Available at: www.anthim.com/download/pdf/ANTHIM-prescribing-information. pdf. Accessed October 4, 2016.
15. Zepatier (elbasvir/grazoprevir) prescribing information. Whitehouse Station, New Jersey: Merck; 2016. Available at: www.merck.com/product/usa/pi_circulars/z/zepatier/ zepatier_pi.pdf. Accessed February 13, 2016.
16. Yondelis (trabectedin) prescribing information. Horsham, Pennsylvania: Janssen Biotech; 2015. Available at: www.yondelis. com/prescribing-information.pdf. Accessed February 13, 2016.
17. Beroukhim K, Abrouk M, Farahnik B. Impact of the Pregnancy and Lactation Labeling Rule (PLLR) on practicing dermatologists. Dermatol Online J 2015;21(11). pii: 13030/qt46c4m2tw.
18. Food and Drug Administration. FDA issues final rule on changes to pregnancy and lactation labeling information for prescription drug and biological products. December 3, 2014. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425317.htm. Accessed February 13, 2016.